As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
In this webinar, moderated by David Carr of PRECISIONadvisors, we explore these challenges and discuss solutions so innovative therapies can get to the patients who need them.
We’ll be joined by a panel of global payer experts across Precision Value & Health, including Jeremy Schafer (US), Olaf Koester (Canada), and Oriol Sola-Morales (Europe).
The discussion will be followed by a live Q&A.